| Mr Ronald Robert Lessard, RPH | |
|
436 Central St, Franklin, NH 03235-1777 | |
| (603) 934-2550 | |
| (603) 934-7120 |
| Full Name | Mr Ronald Robert Lessard |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 436 Central St, Franklin, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730291238 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 2140 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Ronald Robert Lessard, RPH 12 Frances St, Franklin, NH 03235-2120 Ph: (603) 934-2550 | Mr Ronald Robert Lessard, RPH 436 Central St, Franklin, NH 03235-1777 Ph: (603) 934-2550 |
News Archive
Nine research projects, two from Germany, two from Spain and one each from France, Hungary, the Netherlands, Portugal and the UK, have been awarded access to the PRACE Research Infrastructure. In total 362.8 Million compute core hours were granted for the JUGENE, IBM BlueGene/P, hosted by the Gauss-Centre for Supercomputing member site in Jülich, Germany, which is the first Petascale HPC system available to researchers through PRACE.
The communication struggles of children with autism spectrum disorder can drive parents and educators to try anything to understand their thoughts, needs and wants. Unfortunately, specialists in psychology and communication disorders do not always communicate the latest science so well.
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.
Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.
› Verified 9 days ago
Benjamin Gray, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 861 Central St, Franklin, NH 03235 Phone: 603-934-0225 | |
Jyothirmai R Kasireddy, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 952 Central St, Franklin, NH 03235 Phone: 603-934-2832 | |
Paul Francis Kowalski, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 952 Central St, Franklin, NH 03235 Phone: 603-934-2832 Fax: 603-934-7350 | |
Gerard Roger Gagne, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 951 Central St, Franklin, NH 03235 Phone: 603-934-6862 Fax: 603-934-2093 | |
Jason Payne, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 861 Central St, Franklin, NH 03235 Phone: 603-934-0225 Fax: 603-934-0228 | |
Dr. Matthew William Hackett Jr., PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 951 Central St, Franklin, NH 03235 Phone: 603-934-6862 |